Feasibility study of novel nanoparticles derived from as vaccine adjuvant for cancer immunotherapy.

The feasibility of using nanoparticles derived from extract (Glycyrrhiza NPs) as a vaccine adjuvant for cancer immunotherapy was evaluated. C57BL/6J mice were immunized with ovalbumin (OVA) and Glycyrrhiza NPs. After immunization, splenocytes were incubated with the H-2K epitope peptide of OVA (SL8) and the production of IFN-γ was evaluated. Moreover, an OVA-expressing lymphoma cell line (E.G7-OVA cells) was inoculated into mice after immunization to evaluate the antitumor effect. The immunization of OVA with Glycyrrhiza NPs induced IFN-γ production and completely rejected E.G7-OVA cells. Glycyrrhiza NPs could prime antigen-specific CD8 T-cells resulting in antitumor effects. Therefore, Glycyrrhiza NPs can be an effective vaccine adjuvant for cancer immunotherapy.